Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725107 | SCV000334060 | pathogenic | not provided | 2018-06-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000345653 | SCV000799128 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2018-04-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000345653 | SCV001582821 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2025-01-27 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr679Serfs*20) in the CAPN3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CAPN3 are known to be pathogenic (PMID: 10330340, 15689361). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with limb-girdle muscular dystrophy (PMID: 19364062). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 282536). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000725107 | SCV002018090 | pathogenic | not provided | 2019-06-11 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000345653 | SCV002085545 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2021-06-22 | no assertion criteria provided | clinical testing |